Generic Medicine Info
Indications and Dosage
Adult: 50-300 mg daily.
Intoxication with alcohol, barbiturates or benzodiazepines. Benign prostatic hypertrophy, urinary retention; glaucoma; pyloric stenosis, bowel obstruction; predisposition to seizures or epilepsy. Severe hepatic and renal impairment.
Special Precautions
Avoid abrupt withdrawal. Bradycardia, cardiac, arrhythmias;; hypokalaemia. May impair ability to drive or operate machinery. Monitor LFTs on prolonged use. Pregnancy and lactation.
Adverse Reactions
Dry mouth, stuffy nose, fatigue, drowsiness, dizziness, increased sweating, blurred vision, speech impairment, tremors, heart rhythm disturbances, palpitations, orthostatic hypotension, liver dysfunction, constipation, wt gain, urinary retention, decreased libido, increased thirst, rash, urticaria.
Symptoms: Excitement, restlessness, marked antimuscarinic effects (e.g. dry mouth, hot dry skin, dilated pupils, tachycardia, urinary retention, intestinal stasis), unconsciousness, convulsions and myoclonus, hyperreflexia, hypothermia, hypotension, metabolic acidosis, respiratory and cardiac depression, cardiac arrhythmias. Treatment: Symptomatic and supportive care.
Drug Interactions
Reduced hypotensive effect of guanethidine, clonidine. Additive CNS depression or may potentiate the action of CNS depressants e.g. alcohol, sedatives or hypnotics. Increased effects/toxicity with cimetidine, phenothiazines, haloperidol, SSRIs. May increase effects of oral anticoagulants. Increased risk of arrhythmias with quinidine. Additive toxicity with other anticholinergics.
Potentially Fatal: Severe and sometimes fatal reactions may occur with MAOIs; at least 2 wk should elapse between discontinuance of a TCA or a MAOI and initiation of therapy with other drug class. May increase pressor and cardiac effects of sympathomimetics.
Description: Opipramol is a TCA. It exerts its antidepressant action by blocking the neuronal re-uptake of noradrenaline and serotonin.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Opipramol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in